about
Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Eµ-TCL1 CLL mouse model.Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study.Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia.High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin.Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer.The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.Wrangling with P-values.Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia.Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia.JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia.PPARγ Contributes to Immunity Induced by Cancer Cell Vaccines That Secrete GM-CSFAuthor Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesPublisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesMolecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomesPRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemiaPhase 1 Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple MyelomaTargetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunitiesCDK6 Antagonizes p53-Induced Responses during TumorigenesisPrognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemiaOutcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironmentHow many mice? Design considerations for murine studiesSensitive detection of minimal residual disease in patients treated for early-stage breast cancerTP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroupsA dominant-negative effect drives selection of TP53 missense mutations in myeloid malignanciesActivation of hedgehog signaling associates with early disease progression in chronic lymphocytic leukemiaInterplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
P50
Q35836864-12802F7B-AA63-4648-A597-F09D814EBF1BQ35994289-CA4EE30B-F263-464F-BC8D-9D1126297000Q37079676-2B3849CC-C73B-496B-B3E9-DD1B7F3D7F8FQ37528063-65E2EF23-1786-43AE-8977-DCCE26CEBB3DQ38806498-DC737F4C-988F-498B-AED4-0A77E418EBEFQ46255094-D90C618F-6E8D-4E1C-A73D-AD1F0AC71B97Q47102996-F2E05AED-F9DA-4CC3-AEF3-6CE75EC23835Q48270901-82F1F6F3-EA9B-4DF7-9707-EBB879F28518Q48272108-767BF510-3E46-4015-B86C-E151B6C1B605Q52431551-0FA7FAB8-4D3F-4AE6-9869-F03637AF1A83Q52719979-E68D1A06-FAF0-4DD1-A595-156667C60B22Q52722722-3E8BC159-D2A2-469C-A7C0-A44E5F636B51Q53071474-7D386CD0-4C4F-4D02-A771-D732380A593AQ55516451-FCE9ACEE-98E8-40F4-BFDB-8921EE013018Q57450903-2B58302C-6D59-4593-A873-396AC8FCF504Q57909092-650ADA68-2B69-46D0-AFF4-EC12A78C5306Q57909096-E2DB2EB2-77E4-44FF-88E7-0FAB4C190944Q57909099-1649D03F-3D2E-4704-A660-0E6285E34F14Q58597543-D0968863-EC4E-4FDE-8FB3-AA110C05F4E4Q58609590-588F078F-99B1-4BD6-BEC4-E4069FB70778Q62491658-DD77C11F-2A5B-42A7-9848-3F064D6E920CQ63383536-6AD7727B-1BEB-43D0-96DC-20E02872D06EQ87969933-5F328855-39EF-4C75-90F2-FEBF7B8D9B7DQ89023422-1FFD0B22-692C-4F0A-8FE8-1A52D543FF29Q89030672-BAAF26D0-F07D-4FA5-AEE4-8AC9304BD11FQ89777204-25A1A630-DB73-4185-8743-EB3BDA5D41C0Q90316165-792B82B9-F236-493C-8117-6C9809C47E5EQ91011066-601CEF37-F269-436A-8E38-1B7B6055F052Q92508672-8CC7C140-FEF6-4A97-8CCF-D6EE98DA9E52Q92686162-B1164A75-D490-4C77-934A-F58124649A37Q96023037-1C10A6CB-3600-4127-8122-2FC78BAD2F1B
P50
description
investigador
@es
researcher
@en
name
Donna Neuberg
@en
type
label
Donna Neuberg
@en
prefLabel
Donna Neuberg
@en
P31
P496
0000-0003-2566-3145